A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers
Filippo Spriano(Institute of Oncology Research), Francesco Bertoni(Ente Ospedaliero Cantonale), Francesco Trapasso(Magna Graecia University), Alberto J. Arribas(Institute of Oncology Research), Beat Bornhäuser(University Children's Hospital Zurich), Greta Guarda(Università della Svizzera italiana), Luciano Cascione(Institute of Oncology Research), Alberto Furlan, Laura Barnabei(Inserm), Christoph Driessen(University of Zurich), Stefano Alcaro(Magna Graecia University), Roberta Rocca(Magna Graecia University), Giosuè Costa(Magna Graecia University), Antonio Lupia(Magna Graecia University), Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giampietro Viola(University of Padua), Matilde Guala, Francesco Paduano(Magna Graecia University), Keyvan Rezaï(Hôpital René Huguenin), Giulio Sartori(Institute of Oncology Research), Anastasios Stathis(Princess Margaret Cancer Centre), Franco Cavalli(Institute of Social and Preventive Medicine), Jacopo Sgrignani, Gaetanina Golino(Institute of Oncology Research), Samuel Huguet(Institut Curie), M. van den Nieuwboer(Capgemini (Netherlands)), Susana Cristóbal(Stockholm University), Chiara Tarantelli(Institute of Oncology Research), Natalina Pazzi, Digvijay Gahtory(Capgemini (Netherlands)), Meagan R. Tomasso(Drexel University), Francesco Margheriti(Institute of Oncology Research), Ana Maria Carrasco Del Amor(Linköping University), Shae B. Padrick(Drexel University), Nathaniel I. Martin(Leiden University), Andrea Cavalli, Luuk M. Verdonk(Leiden University), Pedro Ventura, Emanuele Zucca(Università della Svizzera italiana), Eugenio Gaudio(Institute of Oncology Research), Paolo Innocenti, María E. Riveiro, Roberta Bortolozzi(University of Padua)
Cited by 5
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431
Artificial intelligence for natural product drug discovery
|Nature Reviews Drug Discovery|2023|380